
CAS 1453848-26-4
:GDC-0994
Description:
GDC-0994, with the CAS number 1453848-26-4, is a small molecule inhibitor primarily targeting the mitogen-activated protein kinase (MAPK) pathway, specifically the extracellular signal-regulated kinase (ERK). It is designed to interfere with the signaling pathways that are often dysregulated in various cancers, making it a candidate for cancer therapy. The compound exhibits selective inhibition of ERK, which is crucial for cell proliferation and survival. GDC-0994 has been evaluated in preclinical studies and clinical trials for its efficacy in treating tumors with specific genetic mutations. Its pharmacological profile includes properties such as oral bioavailability and a favorable safety margin, although detailed toxicity and side effect profiles are typically assessed during clinical development. The compound's structure features a unique arrangement of functional groups that contribute to its binding affinity and specificity for the target enzyme. Overall, GDC-0994 represents a promising approach in targeted cancer therapy, particularly in the context of personalized medicine.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-{2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl}pyridin-2-one
CAS:Formula:C21H18ClFN6O2Purity:98%Color and Shape:SolidMolecular weight:440.8580Ref: IN-DA00ABK7
1mg65.00€2mg93.00€5mg111.00€10mg163.00€25mg232.00€50mg521.00€100mg625.00€250mgTo inquireGDC-0994
CAS:<p>GDC-0994</p>Formula:C21H18ClFN6O2Purity:99.98% (Typical Value in Batch COA)Color and Shape: yellow solidMolecular weight:440.86g/molRavoxertinib
CAS:<p>Ravoxertinib (GDC-0994) is an effective and orally available ERK1/2 inhibitor (IC50: 1.1/0.3 nM).</p>Formula:C21H18ClFN6O2Purity:98% - 99.87%Color and Shape:SolidMolecular weight:440.86




